We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

87 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

6% more capital invested

Capital invested by funds: $244M → $259M (+$14.7M)

1% more funds holding

Funds holding: 8687 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.73% less ownership

Funds ownership: 111.31%109.58% (-1.7%)

Holders
87
Holders Change
+1
Holders Change %
+1.16%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
9
Increased
36
Reduced
25
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$37.7M -$1.86M -43,233 -5%
Bank of America
2
Bank of America
North Carolina
$35.6M +$6.2M +144,084 +22%
Wells Fargo
3
Wells Fargo
California
$20.6M +$1.24M +28,776 +7%
AWA
4
ARS Wealth Advisors
Florida
$13.6M +$930K +21,618 +8%
Brown Advisory
5
Brown Advisory
Maryland
$11.7M +$904K +21,015 +9%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$11.6M +$422K +9,816 +4%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$9.77M +$6.45K +150 +0.1%
RJFSA
8
Raymond James Financial Services Advisors
Florida
$8.2M +$258 +6 +0%
SFI
9
SPC Financial Inc
Maryland
$8.12M -$12.6K -294 -0.2%
U
10
UBS
Switzerland
$7.94M +$556K +12,933 +8%
LPL Financial
11
LPL Financial
California
$6.68M -$806K -18,732 -11%
BWM
12
Braver Wealth Management
Massachusetts
$6.49M -$347K -8,061 -5%
RJA
13
Raymond James & Associates
Florida
$6.19M +$1.33M +31,011 +29%
ST
14
Spinnaker Trust
Maine
$6.02M +$62.1K +1,443 +1%
MCM
15
Murphy Capital Management
New Jersey
$5.75M -$13.5K -315 -0.2%
Goldman Sachs
16
Goldman Sachs
New York
$5.71M +$1.97M +45,885 +57%
SAM
17
Stringer Asset Management
Tennessee
$5.33M -$621K -14,442 -11%
VKH
18
Virtu KCG Holdings
New York
$3.55M +$2.82M +65,634 +498%
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
$2.89M +$105K +2,442 +4%
AIG
20
American International Group
New York
$2.68M -$234K -5,448 -8%
PAMU
21
Pictet Asset Management (UK)
United Kingdom
$2.46M -$51.6K -1,200 -2%
EC
22
Estate Counselors
Wisconsin
$2.34M -$148K -3,450 -6%
OC
23
Oppenheimer & Co
New York
$2.31M +$1.61M +37,341 +267%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$2.17M -$187K -4,353 -8%
PAG
25
Pinnacle Advisory Group
Maryland
$2.17M +$2.07M +48,093 New

IHE Hedge Fund Activity: Q2 2014 in Review

87 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2014, worth a combined $259M — up 6% from $244M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IHE positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Bank of America, adding an estimated $6.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $7.92M sold.

  • 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2014, up from 86 in Q1 2014.
  • Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q2 2014, up 6% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2014 and 8 closed out, a net change of +1 holder.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2014 was Bank of America, an estimated $6.2M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2014 was Clark Capital Management Group, an estimated $7.92M sold.

Based on aggregated 13F filings for Q2 2014.